Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study

Indian Journal of Dermatology, Venereology and Leprology

Volumn 71, Issue 6, 2005, Pages 398-400

  Mangla, Kanu ^a   Rastogi, Swati ^a   Goyal, Puneet ^a   Solanki, Rekha B ^a   Rawal, Ranjan C ^a,b  

^a VS Hospital   (India)

^b Shraman Apartments ^*  (India)

Author keywords

Intravenous immunoglobulins; Toxic epidermal necrolysis

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CARBAMAZEPINE; COTRIMOXAZOLE; FAS LIGAND; IMMUNOGLOBULIN; PARACETAMOL; PHENYTOIN;

APOPTOSIS; ARTICLE; BODY SURFACE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; MORTALITY; TOXIC EPIDERMAL NECROLYSIS;

EID: 28844501845     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.18943     Document Type: Article

References (18)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Eng J Med 1994;331:1272-85.
2. Sullivan JR, Shear NH. The drug hypersensitivity syndrome. What is the pathogenesis? Arch Dermatol 2001;137:357-64.
3. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4.
4. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of TEN by blockade of CD 95 with human IVIG. Science 1998;282:490-3.
5. Phan TG, Wang RC. Crotty K, Adelstein S. Toxic epidermal necrolysis in AIDS treated with intravenous Immunoglobulin. Aust J Dermatol 1999;40:153-7.
6. Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of Toxic epidermal necrolysis treatment with intravenous immunoglobulins. Br J Dermatol 2000;142:191-2.
7. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam el-A, et al. Prospective non comparative open study from Kuwait of the role of intravenous immunoglobulins in the treatment of Toxic epidermal necrolysis. Int J Dermatol 2004;43:847-51.
8. Marwaha RK, Subramanian C. Intravenous immunoglobulins. Indian J Pract Pediatr 2001;4:300-4.
9. Rutter A, Luger TA. High dose intravenous immunoglobulins: An approach to treat severe immune mediated and autoimmune diseases of skin. J Am Acad Dermatol 2001;44:1010-24.
10. Inamder AC, Palit A. Serious cutaneous adverse drug reactions: Pathomechanism and their implications to treatment. Indian J Dermatol Venerol Leprol 2003;69:205-8.
11. th ed. London: Blackwell Science; 1998. p. 3349-518.
12. Hewitt JM, Ormerod AD. Toxic epidermal necrolysis treated with cyclosporine. Clin Exp Dermatol 1992;17:264-5.
13. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis; clinical and pathophysiological aspects. J Am Acad Dermatol 1991;25:778-86.
14. Kamanbroo D, Schmitz-landgraf W, Czarnetski BM. Plasmapheresis in severe drug induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-9.
15. Redondo P, de Felipe I, de la Pena A, Aramendia JM, Vanaclocha V. Drug induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with N-acetylcysteine. Br J Dermatol 1997;136:645-6.
16. Sheretz EF, Jegasothy BV, Lazorus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis: report of a patient treated with corticosteroid 'Pulse Therapy'. J Am Acad Dermatol 1985;12:178-81.
17. Halebian PH, Corder VJ, Madder MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis without corticosteroid. Am Surg 1986;294:503-12.
18. Tristani-Firouzi P, Peterson JM, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulins in children. J Am Acad Dermatol 2002;47:548-52.